| answer text |
<p>The Department’s National Institute for Health Research (NIHR) is currently recruiting
to 15 clinical trials for people with HER2+ breast cancer via its Clinical Research
Network. The majority of these are commercially funded. To date, a total of 7,986
participants have been recruited to these 15 trials.</p><p>Of the 15 clinical trials,
12 are commercially sensitive, with appropriate cost recovery from the companies.
The data for these commercial trials has been provided from the relevant companies
as ‘commercial in confidence’ hence we are unable to provide details about these trials
such as their titles.</p><p>However, the three clinical trials which are not commercially
sensitive are:</p><p>- Cancer Research UK; NIHR Evaluation, Trials and Studies Co-ordinating
Centre (NETSCC). Title: The UK plasma based Molecular profiling of Advanced breast
cancer to inform Therapeutic Choices (plasmaMATCH);</p><p>- Cancer Research UK. Title:
Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer;
and</p><p>- Medical Research Council. Title: A mechanistic non-invasive imaging study
of HER2 expression in breast cancer using [18F]GE-226 positron emission tomography.</p>
|
|
